{
    "clinical_study": {
        "@rank": "84098", 
        "arm_group": [
            {
                "arm_group_label": "broad spectrum AB +fluids", 
                "arm_group_type": "No Intervention", 
                "description": "Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES"
            }, 
            {
                "arm_group_label": "simvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day  begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)"
            }
        ], 
        "brief_summary": {
            "textblock": "determination of the  effectiveness and the cost-effectiveness of simvastatin(Zocor 40 mg)\n      plus standard therapy (SSCG)versus standard therapy alone in critically ill septic patient\n      from the societal perspective over one year."
        }, 
        "brief_title": "Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Critical Illness", 
        "condition_browse": {
            "mesh_term": "Critical Illness"
        }, 
        "detailed_description": {
            "textblock": "Prospective double blinded randomized controlled study Will be carried out at Ain-Shams\n      university hospital Method: - After approval of the research ethics committee of Ain shams\n      University and obtaining consent from each patient, 100 patients newly admitted to the\n      intensive care unit (ICU) diagnosed to have sepsis/severe sepsis defined by American College\n      of Chest Physicians (ACP) *will be randomized by the clinical pharmacist using a\n      computer-generated randomization sequence with a block size of four into two groups.\n\n      Group I (Control group):-50 patients will be treated according to \"Surviving Sepsis Campaign\n      guidelines (SSCG) (Dellinger, et al. 2013) Group II (Intervention group):-50 patients will\n      be treated according SSCG plus simvastatin.\n\n      Outcomes:- Primary outcome measures: 28 day ICU and hospital mortality.\n\n      Secondary Outcome Measures:\n\n        -  Requirement and length of renal replacement therapy, vasoactive agent support or\n           mechanical ventilation\n\n        -  Total ICU and Hospital duration of stay.(LOS)\n\n        -  Number of patients alive 3, 6, and 12 months\n\n        -  Quality of life (QALY) for 3, 6, and 12 months, survivors"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:-\n\n          1. Age >18 and less than 70\n\n          2. Sepsis for less than 24 hours from ICU admission\n\n        Exclusion criteria:-\n\n          1. Elderly (defined as older than 70).\n\n          2. Pediatrics (defined as younger than 18).\n\n          3. Pregnancy and nursing.\n\n          4. Unable to receive enteral medications.\n\n          5. History of hypersensitivity to the trial drug.\n\n          6. Are receiving drugs known to interact with simvastatin.\n\n          7. Acute liver failure and chronic liver disease (Child C).\n\n          8. High risk of rhabdomyolysis (multiple traumas, crush injuries, extensive burns(>60%),\n             baseline creatinine kinase (CK) \u2265ten-times upper limit of normal.\n\n          9. Patients with dyslipidemia or Prior statin user.\n\n         10. Sever renal impairment (defined as need for replacement therapy )and uncontrolled\n             hypothyroidism\n\n         11. Have a history of known or suspected porphyria\n\n         12. Are unlikely to survive more than 24 hours"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067949", 
            "org_study_id": "1/2014"
        }, 
        "intervention": {
            "arm_group_label": "simvastatin", 
            "description": "single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube", 
            "intervention_name": "Simvastatin", 
            "intervention_type": "Drug", 
            "other_name": "Zocor 40 mg"
        }, 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "11361"
                }, 
                "name": "Ain shams university hospital"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Clinical Outcome and the Cost-effectiveness Analysis of Simvastatin Plus Standard Therapy Versus Standard Therapy Alone in Critically Ill Septic Patient\"", 
        "other_outcome": {
            "description": "Requirement and length of renal replacement therapy, vasoactive agent support or mechanical ventilation\nTotal ICU and Hospital duration of stay.(LOS)", 
            "measure": "ICU hazards", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "overall_official": {
            "affiliation": "Ain Shams University", 
            "last_name": "sara M amin, MSC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Health and Population", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "28 day ICU and hospital mortality", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067949"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "sara mostafa amin eladawy", 
            "investigator_title": "teaching assistant", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients alive  and QALY 3, 6, and 12 months", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "sara mostafa amin eladawy", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}